On May 9, 2024, Whitefort Capital Management LP announced that it has engaged with Arbutus Biopharma Corporation, it has conveyed its view to the Company?s?s Board of Directors that the current market price of the shares does not reflect the Company?s intrinsic value, it has requested the Company board to terminate the Company?s ATM program and explore all strategic options for the Company?s hepatitis B virus (HBV) portfolio. In addition, Whitefort Capital stated that it hopes to continue to work constructively and collaboratively with the Board on the critical initiatives and intend to actively engage with shareholders and others regarding their views.